The FDA has approved vimseltinib for tenosynovial giant cell tumor (TGCT) based on the phase 3 MOTION trial led by Dr.

The Food and Drug Administration (FDA) has approved Romvimza ™ (vimseltinib) for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will ...

FDA approves vimseltinib for tenosynovial giant cell tumor and a triplet for R/R LBCL, plus the latest from ASCO GU 2025.

Ono picked up Romvimza—previously known by its active ingredient vimseltinib—from its $2.4 billion acquisition of Deciphera ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA approved the small-molecule inhibitor vimseltinib (Romvimza) for adults with symptomatic tenosynovial giant ...

About MOTION Study The MOTION study is a two-part, randomized, double-blind, placebo-controlled Phase 3 clinical study to assess the efficacy and safety of vimseltinib in patients with TGCT not ...

Discover Vimseltinib, the newly FDA-approved treatment for tenosynovial giant cell tumor (TGCT). Learn about its benefits, ...

The US Food and Drug Administration has approved vimseltinib (Romvimza, Deciphera Pharmaceuticals, LLC) to treat adult ...

Vimseltinib is now an FDA-approved treatment for patients with tenosynovial giant cell tumor, based on findings from the ...